KRAS and colorectal carcinoma: Cologuard® is the first FDA-approved stool DNA test for average-risk CRC screening (in 2014)—a multi-target stool DNA (mt-sDNA) test with high sensitivity which analyzes several molecular markers, including N-Myc Downstream-Regulated Gene 4 Protein (NDRG4) and Bone Morphogenetic Protein 3 (BMP3) methylation status, KRAS mutation and β-actin, combined with FIT for CRC screening.